A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

NCT05615636 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma
B-Cell Lymphoma
Relapsed B-cell NHL

Interventions

DRUG: Mosunetuzumab
DRUG: Polatuzumab vedotin
DRUG: Tafasitamab
DRUG: Lenalidomide

Sponsor

M.D. Anderson Cancer Center